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Results: AV block was asymptomatic in 119 (84.4%) and complete in 100
(70.9%) patients. Incomplete AV block progressed to complete in 29 (70.7%)
patients with incomplete block over 2.8±3.4 years (1-155 months). Narrow
QRS complex was present in 18 of 26 patients (69.2%) with congenital, and
106 of 115 (92.2%) with childhood AV block. Pacemakers were implanted in
112 children (79.4%), during the first year of life in 18 (16.1%) and before 10
years of age in 90 (80.4%). The mean delay between diagnosis of AVB and
pacemaker implants was 2.6±3.9 years (0-300 months). The pacing indication
was prophylactic in 70 children (62.5%). During a median follow-up of
11.6±6.7 years (1-32 years), no patient died or developed dilated cardiomyop-
athy. The long-term follow-up was uncomplicated in 127 children (90.1%).
Conclusions: In this large multicenter study, the long-term outcome of con-
genital or childhood, isolated, non-immune AV block was favorable, regardless of
the patient’s age at the time of diagnosis. No patient died or developed dilated car-
diomyopathy, and pacemaker-related complications were few. The progression of
incomplete to complete AV block in nearly 70% of patients suggests a postnatal
degeneration of the specialized conduction system.
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Right ventricular (RV) failure is a major long-term complication of con-
genital heart disease, leading to morbidity and mortality. Since conventional
therapy gives poor results, cell therapy may be a therapeutic option for cardiac
repair. The ability of embryonic stem cells (ESC) differentiation towards a
cardiomyogenic phenotype makes them attractive candidates. Our aim was to
evaluate, in a large animal model, the effects of cardiac-committed human
ESC transplantation on the RV function.
A model of RV dysfunction was created in 8 piglets using a surgical pro-
cedure mimicking RV tract sequellae of repaired tetralogy of Fallot leading,
after 4 months, to a chronic combined RV overload. Four pigs received
vehicle and 4 others received HUES-24 derived human cardiac progenitors
cells injected at multiple sites into the free wall of RV myocardium. All pigs
were immunosuppressed using tacrolimus. Myocardial function was measured
3 months after cell transplantation by conductance catheter technique using
maximal elastance (Emax) slope and ventricular energetics (stroke work, pres-
sion-volume area). The risk of ventricular arrhythmia was evaluated by pro-
grammed ventricular stimulation at the end of the follow-up. Structural
remodelling was assessed by histological examination.
All pigs survived and no complication occurred related to either myocardial
injections or immunosuppression. No ventricular arrhythmia was induced. In all
treated pigs, myocardial contractility was improved as assessed by an increasing
Emax slope relative to controls at the follow-up end (0.58±0.03 vs 0.40±0.08, p<0.05)
whereas stroke work was similar in both groups. Improvement of contractility in
treated pigs occurred without increasing of pressure-volume area suggesting that the
myocardium is more efficient. In treated pigs, myocardial fibrosis appeared peritra-
becular whereas, in controls, it was found in peritrabecular and perimyocyte areas.
Cell therapy by multiple trans-epicardial injections of ESC derived human
cardiac progenitor cells in failed RV is feasible, improves RV myocardial con-
tractility and allows a better adaptation to chronic overload. 
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Introduction: Congenital long QT syndrome (LQTS) is a frequent cause
of sudden cardiac death in children without structural heart disease. Given the
recent progress in molecular diagnosis, a growing portion of LQTS patients is
genetically affected but still asymptomatic. Their clinical outcome has not
been clearly evaluated, and their optimal treatment is still discussed.
Methods: Our database was searched for all patients with genotyped
LQTS, identified by familial screening and aged 16 or less at diagnosis. We
retrospectively recorded demographic and electrocardiographic data, personal
and family histories and genetic diagnoses.
Results: 90 non proband children with genetically confirmed LQTS were
included. Mean age at diagnosis was 7,3±5,2 years, and mean follow-up dura-
tion was 4,6±4,3 years. 7 (7,8%) were symptomatic before diagnosis, and
4 (4,4%) experienced LQTS-related symptoms during follow-up. No sudden
cardiac death was reported. One LQT1 patient presented aborted cardiac arrest
while swimming. Beta-blocker therapy was initiated in 51 patients (56,7%).
Device therapy was infrequently used (one pacemaker, no implantable cardio-
verter defibrillator). Corrected QT interval (QTc) was the only factor corre-
lated to the risk of LQTS-related symptom (p=0,02). Initiation of betablocker
therapy was associated with mutations in KCNQ1 or KCNH2 (p<0,01), family
history of LQTS-related cardiac event in a first-degree relative (p=0,02), diag-
nosis before four months of age (p=0,01) and a longer QTc (p=0,0016).
Conclusion: Clinical outcome is favorable in genetically confirmed non
proband LQTS children, and similar to what has been previously described despite
less frequent use of beta blocker and device therapies. Thus, beta blocker therapy
should probably not be initiated systematically in such patients, especially when
QTc duration does not exceed 460 ms. ICD implantation does not seem manda-
tory in non proband LQT3 children, at least in their first years of life.
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Background: Managing vitamine K antagonist (VKA) therapy is chal-
lenging especially in children because of a narrow therapeutic range and a
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